Chamber Approves Warning on Medications That May Impair Driving Ability
The Health Commission of the Chamber of Deputies took an important step for traffic safety by approving a project that requires warnings on the labels, package inserts, and advertising materials of medications capable of affecting the ability to drive.
The measure, which aims to raise consumer awareness about the risks of combining driving and certain medications, was included as a substitute by the rapporteur, Deputy Rogéria Santos (Republicanos-BA), to Bill 877/24, authored by Deputy Juninho do Pneu (União-RJ).
“The use of medications associated with driving can significantly increase the risk of traffic accidents,” stated the rapporteur. She emphasized that the initiative will allow consumers to make safer decisions, reducing the likelihood of accidents.
-
Peugeot publicly acknowledged the errors of the PureTech engine, which caused serious failures in hundreds of thousands of cars, and introduced the new Turbo 100 as a definitive solution, a 1.2 turbo tested for over 3 million kilometers that replaces the faulty belt with a more durable chain.
-
Automatic cars become ‘cheap’ in Brazil, and models from Toyota, Hyundai, Nissan, and Honda appear for R$ 65,000 with up to 120 hp, CVT transmission, 482 liters of trunk space, keyless entry, and six airbags to tackle traffic without a clutch.
-
Honda revives a classic from Brazilian streets with a new name, TFT panel, and reprogrammed engine in the 2027 lineup; see the first impressions of the CB500 Hornet, which arrives with 49.6 hp, 4.5 kgf.m torque, 6-speed gearbox, 175 kg, and Showa suspension on Brazilian streets.
-
Without relying on an outlet, without a cable, and without the gasoline engine driving the wheels: Nissan created the Note e-POWER, a hatchback that always runs on an electric motor while a combustion engine works only as a generator, delivering to Japan a type of “electric without recharging” that Brazil is almost unfamiliar with.
The proposal amends Law 6.360/76, which regulates health surveillance of medications, expanding the requirements to protect drivers and pedestrians.
The wording of the approved text was carefully adjusted to include the mandatory warnings without excessively burdening the pharmaceutical industry.
The proposal reflects the growing concern for traffic safety, especially in light of frequent reports of accidents associated with the misuse of medications that impair reflexes and attention.
Next Steps in Congress
Now, the project goes for analysis, in a conclusive manner, by the Consumer Defense and Constitution, Justice and Citizenship (CCJ) commissions. If approved in these stages, it will still need to pass a vote in the Chamber and the Senate before being sanctioned and becoming law.
Despite the progress, experts warn that the effectiveness of the measure depends not only on the adoption of the warnings but also on raising public awareness and proper enforcement.
One point that raised questions was the deadline for pharmaceutical companies to adapt to the new requirements, which will still be defined in subsequent regulation. This highlights the importance of open dialogue among government, industry, and society.
With the final approval, it is expected that the initiative will contribute to the reduction of accidents related to the use of medications and driving.

Be the first to react!